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Abstract

Duchenne muscular dystrophy (DMD) is a severe neuromuscular disease of skeletal and
myocardial degeneration. Eventually, dilated cardiomyopathy develops from ischemia,
inflammation and fibrosis. Due to the high mortality rate, there is an emerging need to
diagnose DMD cardiomyopathy at early stages. Currently, DMD cardiomyopathy is
diagnosed by imaging investigations and detection of circulating biomarkers. However,
current imaging strategies detect functional and morphological changes but fall short in
detecting molecular changes that underlie this disease. Circulating biomarkers provide
information on the molecular level, but they are not cardiac-specific. Therefore, there is an
emerging need for a biomarker that is endogenous to cardiac tissues. The growth hormone
secretagogue receptor (GHSR) and its ligand, ghrelin are produced by both cardiomyocytes
and vascular endothelial cells and could be an indicator of DMD cardiomyopathy. The
work described in this thesis sought to characterize GHSR as a cardiac-localized biomarker
in DMD cardiomyopathy. Histopathology and confocal imaging using a novel fluorescent
ghrelin analog, Cy5-ghrelin (1-19), were used to investigate changes in cardiac tissue
architecture and GHSR and inflammatory markers in the mdx:utrn-/- mouse model of DMD.
My studies show that GHSR is elevated in mdx:utrn-/- myocardial tissues and correlate
strongly with the macrophage marker F4-80 and the pro-inflammatory cytokine IL-6.
Interestingly, I also show that both ghrelin and des-acyl ghrelin bind to sites in large cardiac
vessels of mdx:utrn-/- which might be an indicator of vascular inflammation. Finally, my
project shows the first report of GHSR in cardiac macrophages. In summary, my work
suggests that, in dilated cardiomyopathy, elevations in GHSR correlate with the
inflammatory phenotype as mediated by both the myocardium and macrophages.
Keywords:
Dilated cardiomyopathy, Duchenne Muscular Dystrophy, GHSR, Inflammation,
Biomarker, mdx:utrn-/
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Lay Summary

Heart disease is the leading cause of death in Canada. It is usually diagnosed by imaging,
such as ultrasound. However, this kind of imaging can miss small changes in the heart that
lead to heart disease. My work has addressed this issue by identifying a protein located in
the heart muscle that may indicate the onset of heart disease. I showed that this protein,
called GHSR, is increased in the heart in a mouse model of heart disease, along with the
degree of inflammation in the heart. My research has shown that there may be more
sensitive ways of detecting heart disease, so that it may be diagnosed at earlier stages.
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Chapter 1

1 Introduction

1.1 Significance of the study
The heart is a muscular organ that pumps blood through the blood vessels of the body. In
doing so, oxygen and nutrients are delivered, and metabolites are excreted. When the cells
that make up the muscular portion of the heart, the cardiomyocytes, become dysfunctional,
the heart becomes inefficient in its ability to pump blood, and the result is cardiomyopathy.
There is a critical need to detect cardiomyopathy in its earlier stages, prior to the onset of
overt symptoms. To address this need, our lab is developing new ways for the molecular
imaging of the heart both in situ and in vivo. We have identified a possible biomarker of
heart disease, the growth hormone secretagogue receptor (GHSR) and its ligand, ghrelin.
Our lab has developed ghrelin analogs as molecular imaging tools that enable the imaging
of GHSR in vivo through PET imaging and in situ through fluorescence microscopy of
tissues. The work described in this thesis uses fluorescence molecular imaging to show that
GHSR is elevated in a type of highly inflammatory and fibrotic dilated cardiomyopathy in
a mouse model of muscular dystrophy, implicating the ghrelin/GHSR system as a
biomarker in cardiomyopathy.

1.2 Cardiovascular disease
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Cardiovascular disease (CVD) remains one of the greatest burdens of human disease and
mortality globally1. In Canada, CVD is responsible for 19.7% of total annual death.
Therefore, CVD places a heavy burden on the Canadian health care system which is
estimated at $29 billion per year.2 3
A wide array of conditions is classified as cardiovascular disease: peripheral blood vessel
diseases, coronary artery diseases, arrhythmia, inflammatory heart disease and
cardiomyopathy. To diagnose and treat each of these complex conditions, innovative
approaches are required .4 5 Although coronary artery disease is the largest contributor to
cardiovascular diseases, cardiomyopathies are clinically very devastating. 6 For example,
50% of cardiomyopathy patients die suddenly in their childhood or adolescence.7

1.3 Cardiomyopathies
Cardiomyopathies are structural myocardium abnormalities associated with cardiac
dysfunction. Cardiomyopathies are categorized based on their morphology and function
into hypertrophic, restrictive, dilative and arrhythmogenic right ventricular subtypes which
might overlap genetically and phenotypically. 2 8
Hypertrophic cardiomyopathy is a disorder in which the ventricular wall thickness or mass
is increased in the absence of a loading condition such as hypertension or valve disease.
Myocyte hypertrophy occurs due to interstitial inﬁltration or intracellular accumulation of
metabolic substrates.9 10 11
Restrictive cardiomyopathy refers to a pattern of ventricular filling that results in
myocardium stiffness and causes a precipitous rise in ventricular pressure. RCM is difficult

3

to define since it occurs in numerous pathologies.

But based on more specific

classification, RCM is characterized by restrictive ventricular physiology in the presence
of reduced systolic and diastolic volume with normal ventricular wall thickness. 12 13 14
Arrhythmogenic right ventricular cardiomyopathy is defined by progressive substitution of
right ventricular myocardium by adipose and fibrotic tissue with associated arrhythmia.
These pathologic and histologic abnormalities are a result of disruptions to the inflow and
outflow of blood through the right ventricle. 8 15 16 17
Dilated cardiomyopathy (DCM) is the most common subtype of cardiomyopathy due to its
involvement with other diseases and it is the focus of this thesis.

1.4 Dilated Cardiomyopathies
DCM is a serious clinical concern due to its high prevalence and the high likelihood of
heart failure (HF) in the later stages of the patient’s life. The prevalence of DCM is
estimated to be at least 1:2500; it is the third most common cause of heart failure and the
most frequent cause of heart transplantation.2 18 However, DCM is underdiagnosed as some
patients remain asymptomatic until marked ventricular dysfunction takes place; therefore,
the prevalence may be as high as 1:250.19 20
DCM is characterized by dilation of the left ventricle and systolic dysfunction. The
ventricular myocardium, mainly the left ventricle, undergoes a combination of thinning
and stretching which results in chamber enlargement and impaired contractility. This
structural change leaves the patients at higher risk of HF which could spread to the other
heart chambers. The DCM patients suffer from symptoms such as swelling of the lower
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extremities, fatigue, shortness of breath, arrhythmia and valve problems.21 The typical age
of occurrence is between 20 to 60 years, and it is more prevalent in men than women. 22 23
DCM could be genetic and non-genetic. The non-genetic DCM may occur as a result of
bacterial and viral infections or autoimmunity.

19 24

In genetic DCM, the mode of

inheritance is typically autosomal and X-linked. The autosomal forms of DCM are caused
by mutations in the genes that encode cytoskeletal (actin, myosin, tropomyosin, troponin
I, troponin C, troponin T and vinculin), sarcomeric (sarcoglycan) and nuclear (lamin) and
Z-band (titin) proteins. DCM also occurs in mitochondrial cytopathies.17 19 24 Additionally,
neuromuscular disorders such as Duchenne muscular dystrophy (DMD) and Becker
muscular dystrophy (BMD) are X-linked muscular disorders which exhibit the DCM
phenotype. 21 25 The focus of this thesis is DMD dilated cardiomyopathy.

1.5 DMD Dilated Cardiomyopathy
1.5.1 Duchenne Muscular Dystrophy

Duchenne muscular dystrophy (DMD) affects approximately 30,000 boys in North
America, making it the most fatal disorder in early childhood.26 It is an X-linked
neuromuscular disease caused by mutations in the gene encoding dystrophin.
Dystrophin is one of the largest human proteins with a molecular weight of 427 kDa and
is located within myocytes on the cytosolic side of the sarcolemma. Dystrophin acts as a
bridge to connect the cytoskeletal F-actin to laminin in the extracellular matrix and is an
important component of the dystrophin-associated protein complex or DAPC, that is also
composed of dystroglycans, dystrobrevins, sarcoglycans, and syntrophins (Figure 1). This
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vital complex is a crucial link between the extracellular matrix (ECM) and the intracellular
actin cytoskeleton and serves two functions: to maintain the structural integrity of the
muscle fiber and to act as a scaffold for signaling proteins. Through interactions with
dystrophin, several structural proteins provide stability, deformability and muscle integrity
during skeletal muscle and cardiac contraction.27 28 A major signaling protein is neuronal
nitric oxide synthase (nNOS), which is localized to the sarcolemma by dystrophin and
catalyzes the synthesis of nitric oxide (NO), which facilitates vasorelaxation.

Figure 1: Dystrophin links the ECM to cytoskeletal and signaling proteins.
This schematic illustrates the key location of dystrophin (green) at the sarcolemma
of a myocyte, where it mediates interactions between the DAPC, the actin
cytoskeleton and the intracellular signaling protein nNOS. 29 30

1.5.2 DMD Cardiac Pathology
The absence of dystrophin in skeletal muscle is the cause of Duchenne muscular dystrophy
(DMD). One complication of DMD is dilated cardiomyopathy, characterized by a
combination of ischemia, inflammation and fibrosis that is caused by an absence of
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dystrophin in cardiomyocytes. These cardiac cells comprise the involuntary striated muscle
(myocardium). Compared to skeletal myocytes, cardiomyocytes are short and branched
and connected to their neighbors via intercalated disks, forming a strong, contractile muscle
network.
Located within the sarcolemma of cardiomyocytes are L-type calcium channels which
promote the influx of calcium ions from the extracellular matrix into the cells and
contribute to the depolarization of the cardiomyocytes to maintain and generate contractile
action.31 The absence of dystrophin leads to the loss of integrity of the sarcolemma and
shearing during myofiber contraction.32

33

The damaged membrane allows for abnormal

calcium ion influx that activates calpain proteases, which can auto-digest the
cardiomyocytes. Calpain proteases also degrade cardiac troponin I, part of the troponinactin-tropomyosin complex that mediates contractility.27 34
The abnormal calcium flow in cardiomyocytes also increases the level of reactive oxygen
species, which stimulates the NF-B signaling pathway, triggering the release of proinflammatory cytokines and resulting in immune response at the site. Subsequently,
macrophages are recruited to the tissue for cell debris removal. Macrophages also attack
the cardiac myofibers, thus exacerbating the sarcolemmal damage and leading to
myonecrosis. Macrophages are the most abundant immune cells in DMD cardiac muscle
and both M1 (pro-inflammatory) and M2 (regenerative) phenotypes are present at the site
of cardiac injury. T-cells, B-cells and dendritic cells also found at the site, with CD4+ Tcells being predominant to CD8+ T-cells in DMD heart. Furthermore, in the process of
myonecrosis, inflammatory macrophages release pro-inflammatory cytokines, which
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triggers the fibroblasts in the extracellular matrix to produce collagen, leading to fibrosis.35
36 37

The pro-inflammatory cytokines TNF-α and IL-6 are elevated in the plasma of DMD
patients.38 TNF-α is associated with T-helper cells type-1 (Th1) and is upregulated 1000
times in DMD patients compared to healthy people. Studies have shown higher mRNA
expression of TNF-α in the lymphocytes of DMD patients.39 As well, in a mouse model of
DMD, the diaphragm contains a significant amount of TNF-α mRNA, and TNF-α
colocalizes strongly with macrophage infiltrates.40
IL-6 is another pro-inflammatory cytokine that is elevated in DMD patients. It is associated
with T- helper cells type 2 (Th2). IL-6 exerts its pro-inflammatory effects via activation of
the NF-B pathway.40 The concentration IL-6 is 4 times higher in the serum of DMD
patients compared to the aged-matched controls. The levels of IL-6 mRNA in DMD
skeletal muscles is significantly higher than in healthy muscles.41 However, whether IL-6
or TNF-α is elevated in the DMD heart is not known.
Dystrophin also plays a role in maintaining adequate blood flow in the muscle through
regulation of nNOS. Without dystrophin, nNOS does not attach properly to the
sarcolemma; instead, it is mislocalized to the cytosol, where it activates metabolites that
function in vasoconstriction, leading to inadequate blood flow and muscle ischemia. In
addition, dystrophin deficiency in vascular smooth muscle cells also negatively impacts
vasoregulation.42 43
As a result of progressive loss of contractile function, increasing fibrosis and ischemia, the
cardiac muscle regenerative capacity decreases with age, and the cardiac myofibers are
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gradually replaced by connective and adipose tissues,

44 45

eventually resulting in

conduction defects and dilated cardiomyopathy after 10 years of age.46 The progression of
this cardiac defects worsen over time and will be present in all patients by 18 years of age
and leading progressively to heart failure and is present in about 90% of patients. Initially,
DMD patients have a normal heart but eventually, the inferobasal wall becomes fibrotic
leading to hyper-trabeculation and dysfunction of the left ventricle which results in
decreased contractility. Unfortunately, the cardiac complication of DMD is largely
asymptomatic until heart function is severely hindered. 26 27 33 47

1.5.3 Pre-clinical models of DMD
Animal models play a vital role in pre-clinical diagnostic and therapeutic research and
provide insights into disease mechanisms. To study DMD, there are numerous mammalian
models, including canine, feline and mouse models. The canine X-linked muscular
dystrophy model demonstrates a rapid progressive muscular phenotype along with a slow
progression to the left ventricular dilation and decreased systolic function. However, the
canine model shows a variable disease severity and cardiac involvement and fibrosis that
only occur after several years. 48 25 49 50 The hypertrophic feline muscular dystrophy model
exhibits prominent hypertrophic muscle phenotype but very slight cardiac involvement.
Therefore, the feline model is not translatable to the human cardiac condition. Additionally,
both models are relatively large and require sophisticated and costly housing which is
problematic for research use. 25 49 51

1.5.3.1 Mouse models of DMD
Rodent models, specifically mice, have become popular in research due to the wide range
of inbred and genetically modified strains that resemble DMD in humans. There are
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numerous single-knockout and double-knockout DMD strains, such as knockouts of
dystrophin alone (mdx), or in combination with utrophin (mdx:utrn-/-), α7-integrin
(mdx:itga7-/-), MyoD (mdx:myod-/-), desmin (mdx:des-/-), dystrobrevin (mdx:adbn-/-),and
parvalbumin (mdx:pv-/-).25 52 53
By far, mdx mouse is the most widely DMD model. Similar to DMD patients, the mdx
mouse has a nonsense mutation in the X-chromosome dystrophin gene which results in
halting the synthesis of the dystrophin protein. Hence, the mdx mice are greatly applicable
in skeletal muscle research. However, strain’s applicability for DMD cardiomyopathy
research is limited, since the mdx model exhibits mild and non-progressive cardiomyopathy
only after 10 months of age. The mild phenotype of mdx mice may be due to the
upregulation of the protein utrophin, which is the dystrophin homolog. Utrophin
structurally substitutes and partially compensates for dystrophin in the DAPC in mice, but
not in humans.53 54 55
In contrast, the mdx:utrn-/- mouse model, which is deficient in both dystrophin and utrophin
production, demonstrates severe skeletal muscle degeneration along with cardiac
dysfunction which phenocopies the human condition. These mice also exhibit abnormal
gait, hind limb weakness, kyphosis, abnormal ECG and respiratory failure. They generally
fail to survive after 20 weeks of age. The development of cardiomyopathy in these mice
has been mapped using different imaging modalities such as 3D ultrasound and computed
tomography (CT) perfusion. 25 56 57 58 59

1.6 Imaging Modalities for detecting DCM
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Diagnosis of cardiomyopathy in DMD is difficult since the patients have reduced exercise
tolerance that masks the cardiac problem. DMD patients suffer from immobility,
pulmonary failure, and scoliosis, which obscures the clinical and radiographic symptoms
of heart failure.

37 60

Clinically, cardiac involvement is mainly diagnosed at later stages

through electrocardiography and echocardiography and sometimes detected by cardiac
magnetic resonance imaging (MRI), computed tomography (CT) and radionuclide
imaging.61 62 63 64

1.6.1 Electrocardiography and Echocardiography
Electrocardiography (ECG) and echocardiography are common clinical imaging tools used
to identify the structural and functional cardiac changes. ECG analyzes the electrical
activity within the heart while echocardiography assesses cardiac function by ultrasound
imaging. It is frequently used to elucidate changes in heart shape and size, along with the
excess fluid characteristics (pulmonary congestion, pleural effusion). ECG detects left
ventricular hypertrophy and cardiac arrhythmias that indicate the onset of
cardiomyopathies that can lead to heart failure.26 65
Echocardiography is also a powerful diagnostic tool that gives information about the
ventricular size and valvular abnormalities. It enables clinicians to diagnose
cardiomyopathy by measuring cardiac systolic function by ejection fraction (EF) which
represents the fraction of blood pumped out of the ventricle with each heartbeat. 37 62 66 67
Both techniques are relatively cost-effective and widely used in clinics. However, they
provide information on structural changes that occur in the later stages of heart disease,
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when the patient is experiencing outward symptoms. Additionally, echocardiography
requires professional acquisition and images might be variable based on the observant
expertise.65 61 68

1.6.2 Cardiac MRI and CT
Cardiac MRI detects early structural changes in DCM. It reveals three-dimensional
information regarding heart size, the thickness of the ventricular wall, and function
information such as ejection fraction, blood flow, fibrosis, edema, hemorrhage and changes
in soft tissue. MRI is an invaluable tool which is used to diagnose and evaluate cardiac
muscle abnormalities at an early stage in a non-invasive manner without exposure to
radioactivity. In the clinic, gadolinium contrast-enhanced MRI aids in identifying areas of
myocardial fibrosis. However, it cannot detect the diffuse fibrosis which is notable in DMD
cardiomyopathy. Also, MRI for DMD patients may be limited, as many patients bear
assistive implanted devices as mobility aids, which are not compatible with MRI.69 70 71
CT is another imaging modality which yields three-dimensional high resolution anatomic
and morphologic information. Image contrast is dependent on the degree of x-ray
attenuation by different tissues and can be enhanced by the injection of barium or iodinebased contrast agents. Contrast-enhanced CT has extremely high resolution and is excellent
for imaging blood vessels, especially coronary arteries. Contrast agents are also used for
coronary angiography to visualize arterial stenosis. Another type of CT, CT perfusion,
measures myocardial blood flow and blood volume. The main concern to use the contrastenhanced CT is the risk of radiation exposing the children with DMD. As the acceptable
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radiation dosage for the DMD children has not been determined. The contrast agent may
also cause an allergic reaction. 72 73 74
To date, all standard diagnostic imaging tools for the detection of DMD cardiomyopathy
yields information on structural changes in the heart. What is missing are indicators of the
progression of heart disease at a molecular level, which can potentially detect the onset of
cardiomyopathy at earlier or subclinical stages. 25 Therefore, from a clinical point of view,
there is a critical need for tissue biomarkers that can identify the different stages of
cardiomyopathy and predict the response to the therapy.

1.7 Biomarkers for DCM
Biomarkers are measurable indicators of biological conditions and may potentially identify
the molecular mechanisms at different stages of cardiomyopathy progression. Ideally, a
cardiac biomarker should comprise qualities such as: 1. Provide accurate and repeatable
measurements; 2. Be present at early stages of cardiomyopathy pathogenesis; 3. Be highly
sensitive to sub-clinical cardiac changes; 4. Be Cardiac-localized and 5. Be Metabolically
stable and not be degraded. 69 71 75 Currently, natriuretic peptides and cardiac troponins are
clinically used as biomarkers for DMD cardiomyopathy.60 76 Specifically, elevated levels
of circulating brain natriuretic peptide (also known as B-type natriuretic peptide, BNP), Nterminal pro-BNP (NT-pro-BNP) and cardiac troponins I & T indicate cardiomyocyte
stress and injury and are used as a diagnostic tool for HF and DCM patients.
The hormone BNP, along with NT-pro-BNP, is secreted by ventricular cardiomyocytes
upon increased wall stretching, and pressure overload as occurs in DCM. Both BNP and
NT-proBNP are produced by the post-translational processing of proBNP, and N-terminal
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pro-BNP is more stable than BNP in plasma. Plasma BNP levels of more than 100 pg/mL
and NT-pro-BNP levels of more than 900 pg/mL are indicators of heart dysfunction. 77 78
While BNP is commonly used as a diagnostic tool in the clinic, there are several limitations
to its use as a biomarker for cardiomyopathy. First, BNP is a biomarker for severely
depressed Left Ventricular Ejection Fraction (LVEF) but not for early-stage dysfunction in
the left ventricle. Therefore, it cannot determine early stages of the cardiomyopathy.78

79

Second, there are other non-cardiac factors that affect circulating levels of BNP such as
obesity and renal failure .80 81 Both BNP and NT-pro-BNP are also elevated in the plasma
with age. These results suggest that elevated BNP levels may not be specifically due to
cardiomyopathy and may vary depending on disease severity and genetic polymorphism.
The other biomarker is troponin that is a regulatory protein and present in the myofibers
of striated muscles. It comprises three subunits that are products of different genes: C, I
and T. Troponin C is not specific to cardiac muscle and it is not used in the clinic since its
isoform is shared by skeletal muscle. Cardiac troponin I and cardiac troponin T are
biomarkers of cardiac stress and historically used to diagnose myocardial infarction. While
increases in circulating levels of both cardiac troponins I and T are associated with
myocardial necrosis and remodeling, the assay for troponin I assay is the most sensitive
and specific test in the clinic.82 In DMD, increased cardiomyocyte sarcolemma
permeability and stretching leads to the release of troponins from the cytosolic pool.
Furthermore, an increase in cardiac ventricular wall stress causes cardiomyocyte apoptosis
and disruption of the contractile force resulting in troponin release. However, cardiac
troponins are also elevated in other cardiovascular diseases such as hypertrophic
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cardiomyopathy, hypertension, myocarditis and cardiac amyloidosis and only provide
information at the late stages of DMD cardiomyopathy. 75 83 84
Although both circulating biomarkers are detectable by a simple blood test, they are not
specific to the heart and may be produced by other tissues in response to injury. Moreover,
circulating levels might not be representative of those found within the cardiac tissue.
Therefore, it is necessary to identify cardiac- localized biomarkers for DMD
cardiomyopathy. 68
One possible biomarker is the cardiac-localized is the growth hormone secretagogue
receptor (GHSR) and its ligand, ghrelin. I will now elaborate on the ghrelin/GHSR system
as a cardiomyopathy biomarker.

1.7.1 GHSR and ghrelin: general physiology
Ghrelin and its receptor, GHSR, represent a potential candidate biomarker for
cardiomyopathy. Ghrelin is a 28 amino-acid peptide hormone and is the natural ligand of
GHSR, a seven-transmembrane, G protein-coupled receptor. This peptide hormone plays
an important role in systemic metabolism by appetite stimulation and food intake
regulation. Ghrelin levels in plasma are raised in the fasted state and reduced after a meal.85
Mature bioactive ghrelin is produced from the post-translational cleavage of pro-ghrelin
(117 amino-acid) and is octanoylated on serine 3 by ghrelin O-Acyltransferase (GOAT),
which enables binding to GHSR. The proportion of ghrelin that does not bear this
modification is termed des-acyl ghrelin and does not bind to GHSR.86

15

Molecular features of ghrelin are located in N-terminal region, particularly in residues 1-8
of the peptide which is required for activation of GHSR.87 The binding of ghrelin to GHSR
induces signaling through Gαq11 which results in growth hormone release.88
Ghrelin was originally isolated from rat and human stomachs, but it is also synthesized in
and secreted from other tissues including those of the cardiovascular system.85 89 Specific
binding of ghrelin in cardiovascular tissues such as myocardium, aorta, coronary arteries,
pulmonary arteries and veins has been reported, demonstrating that GHSR is expressed
throughout the cardiovascular system.90

1.7.1.1

Ghrelin & GHSR in the Cardiovascular System

The expression of myocardial GHSR and the production of ghrelin from cardiomyocytes
and vascular endothelial cells suggests the presence of ghrelin/GHSR system in the heart
that operates independently of its function in the regulation of appetite.89 One study has
shown that ghrelin had effects on the cardiovascular system through GHSR in GH-deficient
rats, further demonstrating the independence of the cardiovascular ghrelin/GHSR system91
92

As well, ghrelin synthesis by the myocardium and cultured cardiomyocytes suggests that

ghrelin could have autocrine and paracrine effects in cardiac muscle.93 94
The binding of GHSR by ghrelin activates numerous signaling pathways that mediate the
cardiovascular effects of ghrelin.95 At the level of the cardiomyocyte, these effects include
the promotion of contractile activity, stimulation of angiogenesis and proliferation, and
inhibition of apoptosis.91
Activation of GHSR by ghrelin results in subsequent activation of phospholipase C (PLC),
which cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) into IP3 and diacylglycerol.
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Diacylglycerol binds to and activates PKC, which then activates L-type voltage-dependent
Ca2+ channels in the sarcolemma, and IP3 facilitates calcium release from the sarcoplasmic
reticulum (SR), which is necessary for cardiomyocyte contraction.95 The binding of ghrelin
to myocardial GHSR also activates other molecular pathways such as PI3K and AKT that
promote angiogenesis, cell proliferation and migration.96 Signaling through PI3K and
ERK1/2 is also associated with inhibiting apoptosis. Ghrelin inhibits apoptosis induced by
doxorubicin in cardiomyocytes by elevation of the antiapoptotic factors IGF-1 and
cardiotrophin-1 (CT-1). Therefore, ghrelin activation of GHSR in cardiomyocytes
promotes contractile activity and survival and inhibits apoptosis.97
Several studies conducted in various animal models of heart disease provide evidence for
the cardioprotective effects of the ghrelin/GHSR system and its potential for diagnosis and
treatment of cardiovascular diseases. Administration of ghrelin in an ischemia-reperfusion
rat model decreased infarct size and improved left ventricular function.

91 98

Ghrelin also

attenuated left ventricular remodeling in rats after myocardial infarction as well as in obese
mice.99

100

In animal models of HF, ghrelin administration improved myocardial

contractility and reduced cachexia.101
In humans, ghrelin administration also improved cardiac output in patients with congestive
HF, suggesting that ghrelin may have a therapeutic role in HF.89 In healthy humans,
intravenous ghrelin injection improved cardiac output and contractility and reduced arterial
pressure with no changes in heart rate.102 Nagaya et al. reported that ghrelin administration
improved left ventricular function by attenuating left ventricular remodeling in chronic HF
patients. They also showed that ghrelin administration reduced the vascular resistance and
improved the stroke index and cardiac output in chronic HF patients.103 They also observed
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that ghrelin treatment boosted the lean body mass, muscle strength, and oxygen
consumption during exercise, suggesting that ghrelin may reduce the extent of muscle
wasting in chronic HF patients.103
Ghrelin action in the vasculature and particularly endothelial cells is complex due to the
activation of different pathways. Ghrelin binding to GHSR on endothelial cells promotes
NO synthesis through activation of PI3K/AKT and eNOS signaling pathways.104 Tesauro
et al. showed that ghrelin could reverse endothelial cell dysfunction in metabolic syndrome
patients through an increase in NO bioavailability, thereby suggesting a role for ghrelin in
vascular hemostasis 105. Signaling through the PI3K/AKT pathway also leads to protection
of endothelial cells against oxidative stress and apoptosis.95 106

1.7.1.2

Ghrelin & GHSR in Inflammation

Ghrelin may have an anti-inflammatory role in the immune and vascular system. Studies
have demonstrated that levels of GHSR are increased in acute vascular inflammation.
Human coronary endothelial cells and smooth muscle cells incubated with
lipopolysaccharide to induce inflammation showed increased GHSR mRNA levels, and
inflammation was attenuated after treatment of the cells with ghrelin.

107

Ghrelin also

hindered the production of the pro-inflammatory cytokine IL-8 and NF-B signaling
activation in human umbilical vein endothelial cells (HUVECs) treated with TNF-α.108
Ghrelin also has direct anti-inflammatory effects on immune cells. It has been shown that
GHSR is expressed in human monocytes and T-cells, and treatment with ghrelin blocks the
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secretion of the pro-inflammatory cytokines IL-1, IL-6 and TNF-α.

109

In vivo, treatment

of a rat model of arthritis with a ghrelin analog for eight days attenuated the level of
inflammation by reducing the plasma concentration of cytokines.110
The anti-inflammatory effect of ghrelin has also been reported in acute myocardial
inflammation. Ghrelin injection ameliorated the inflammatory post-infarction myocardial
remodeling in rats induced by coronary artery ligation. Subcutaneous injection of ghrelin
decreased the left ventricular remodeling and scar thickness and inhibited the inflammatory
response as determined by reductions in mRNA and protein levels of IL-1 and TNF-α. 111
Since ghrelin appears to have cardioprotective and anti-inflammatory effects on
cardiomyocytes and vascular endothelial cells through GHSR, we need to have more
insight into patterns of GHSR changes in cardiomyopathy. Since DMD dilated
cardiomyopathy is a combination of inflammation, ischemia and fibrosis, elucidating the
relationship between inflammation and GHSR in this condition could provide more
insights into the progression of dilated cardiomyopathy.

1.7.1.3

Our GHSR strategy

Our collaborative research group has developed and characterized novel fluorescent tools
for the detection of GHSR in situ. In particular, we have generated peptide analogs of
ghrelin and des-acyl ghrelin conjugated to the far-red fluorophore, Cy5: Cy5-ghrelin (119) and Cy5-des-acyl ghrelin (1-19). Using these tools, our previous work demonstrated
that only the octanoylated form of ghrelin bound to GHSR in murine cardiomyocytes112.
With the Cy5-ghrelin(1-19) probe we were also able to track the differentiation of P19 cells
into cardiomyocytes, demonstrating that we can follow changes in GHSR over time.112
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Using Cy5-ghrelin (1-19), our lab showed that levels of cardiac GHSR decreased in a
mouse model of diabetic cardiomyopathy which represented early-stage DCM113, and
investigated the dynamics of GHSR before and after cardiac transplantation in humans with
end-stage HF. In this important study, we also found an inverse correlation between LVEF
and myocardial GHSR levels and demonstrated that GHSR may be more sensitive than
BNP as a cardiac-localized biomarker for HF. 114
Overall, our lab has identified the GHSR/ghrelin system as a possible cardiac-localized
biomarker for human end-stage HF and the early stages of murine diabetic
cardiomyopathy. These findings led to my study investigating if GHSR is a biomarker in
the highly inflammatory and fibrotic cardiomyopathy of DMD.
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1.8 Central Hypothesis
My studies focused on characterizing changes in GHSR, ghrelin and inflammatory markers
in the heart and cardiac microvasculature, in a mouse model of DMD cardiomyopathy.
Hypothesis: I hypothesize that GHSR levels positively correlate with the severity of
cardiac and vascular inflammation in DMD
The aims of this project are:
1. To characterize GHSR and inflammatory markers in late-stage cardiomyopathy
in a mouse model of DMD
2. To characterize GHSR in mouse vascular endothelial cells and its correlation with
levels of induced inflammation
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Chapter 2

2 Material and Methods

2.1 Animal models
Experiments were performed at The Lawson Health Research Institute at St. Joseph’s
hospital in London, Ontario. All animal protocols were approved (Ethics approval #2008067) by the Western University Institutional Animal Use Subcommittee and conducted
according to guidelines set by the Canadian Council on Animal Care (CCAC).

2.1.1 Wild type (C57BL/6 Mice)
As a negative control, wild-type C57BL/6 mice were purchased from Charles River
Laboratories (Wilmington, MA, USA) at the age of 4-5 weeks and housed at the Lawson
Health Research Institute Animal Care Facility. Mice were maintained in controlled
conditions (19-23˚C, 12-hour light/dark cycles), fed regular mouse chow and monitored
daily to ensure their health. Food and water were provided ad libitum.

2.1.2 Heterozygous mdx mice (mdx:utrn+/-)
Heterozygous mdx mice (mdx:utrn+/-) were generously provided by Dr. Robert Grange,
Virginia Polytechnic Institute and State University, Blacksburg, VA, USA. This strain
was originally generated by Dr. Mark Grady and Dr. Joshua Sanes from Washington
University, St. Louis, MO, USA. Heterozygous utrophin mdx mice (mdx:utrn+/-) have an
intermediate disease phenotype compared to the double knockout mice.115
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2.1.3 Mouse model of DMD mice (mdx:utrn-/-)
Heterozygous mdx mice were crossed to generate mdx:utrn-/-mice which lack both
utrophin and dystrophin. Only male groups of wild-type and mdx:utrn-/- mice at the age of
15-17 weeks were used in this study. At this age range, mdx:utrn-/- mice demonstrate the
severe phenotype of DMD disease 53 and do not tend to live past 20 weeks of age. In this
thesis, the DMD mouse refers exclusively to the mdx:utrn-/- mouse.

2.2 Animal genotype validation
For genotyping, tail snips or ear-notches were collected, and DNA was extracted according
to the standard PCR genotyping protocol. Briefly, tail snips or ear-notches were lysed using
Proteinase K at 55° C overnight. Then, the polymerase chain reaction (PCR) was performed
by Taq polymerase enzyme (Biolabs, M0267E) to amplify the utrophin gene.52
The set of primers that were used to confirm the presence of utrophin were:
5’- TGCCAAGTTCTAATTCCATCAGAAGCTG -3’ (forward primers)
and 5’- CTGAGTCAAACAGCTTGGAAGCCTCC-3’ (reverse primer)
Gene deletion was confirmed by the existence of a band at 310 kb on a 1% agarose gel
containing ethidium bromide.

2.3 Heart sample preparation
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All hearts were obtained from mice from a previous study in which cardiomyopathy had
been measured by determining left ventricular ejection fraction through micro-CT and 3D
echocardiography.59 In that study, the hearts from each of three 15-17 week-old WT and
three mdx:utrn-/- mice were removed immediately after CO2 euthanasia, and fixed in 10%
buffered formalin for 48 hours116. Then, they were cut axially into two equal sections and
embedded in paraffin. Tissue processing and sectioning were done by the Pathology Core
Facility at Robarts Research Institute (Western University, London, Ontario).

2.4 Tissue Sectioning
Tissue blocks were sliced in 5μm serial sections with a total of 40 sections for each block
of cardiac tissue. To ensure that sections were representative of the whole cardiac tissue,
serial sections were taken every 10 slices for histological analysis and fluorescent
staining. The selected tissue sections (5 per heart) were deparaffinized and dehydrated
with a series of xylene, 100%, 90% and 70% ethanol prior to staining.116

2.5 Histological imaging
2.5.1 Image acquisition
Hematoxylin and Eosin (H&E) and Masson’s Trichrome staining was performed by the
Pathology Core Facility at Robarts to qualitatively assess tissue architecture and the level
of fibrosis, respectively. Images were acquired on a Zeiss Axioscope microscope with
Northern Eclipse software v7.0 (Empix Imaging Inc) under 10x, 20x and 40x objectives.
Non-overlapping fields of view were taken to image the entire tissue for each section
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with the 10x objective. As well, the entire tissue section was raster scanned at 10x to
provide an unbiased view of the staining. To have more insight for each section, 6 fields
of view were taken with the 20x and 40x objectives.

2.6 Immunostaining
For immunostaining, heat-mediated antigen retrieval was performed with 10 mM sodium
citrate buffer in Phosphate Buffered Saline (PBS), pH =7.4, for 20 minutes prior to
staining.116 Then, tissues were incubated with blocking buffer (10% Donkey serum
(Sigma-Aldrich, D9663) + 1% bovine serum albumin (BSA) in PBS) for 1 hour at room
temperature. Slides were then incubated with primary antibodies (antibodies are listed in
Table 1 and described in Section 2.6.2) overnight at 4° C followed by incubation with
secondary antibodies (listed in Table 1 and section 2.6.2) for 2 hours at room
temperature. Finally, Cy5-ghrelin (1-19) (1:100) or Cy3-des-acyl-ghrelin (1-19) (1:100)
were added to slides and incubated for 30 minutes.

2.6.1 Designing of fluorescent ghrelin analogs
The fluorescent ghrelin analogs, Cy5-ghrelin (1-19) and Cy3-des-acyl-ghrelin (1-19), were
used to detect GHSR and des-acyl-ghrelin binding, respectively, in the cardiac tissues.
These probes were synthesized as described previously112. Structures are illustrated in
Figure 2.

A

B
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Figure 2. Structure of ghrelin probes. A) Structure of Cy5-ghrelin (1–19);
(Dpr3(octanoyl), Lys19(Cy5) B) Structure of Cy3-des-acyl-ghrelin (1–19).

2.6.2 Antibodies
A) F4-80: For immunofluorescent detection of macrophages, rat monoclonal anti-F4-80
antibody (1:200, Abcam, ab16911) was used and visualized with Alexa Fluor-594
conjugated donkey anti-rat IgG (1:500, Life Technologies, A21209). This antibody targets
the F4-80 antigen (glycoprotein) that is expressed by murine macrophages.
B) IL-6: To demonstrate the acute phase of the inflammatory response, mouse monoclonal
anti-IL-6 (1:100, Abcam, ab9324) was used, followed by Alexa Fluor-594 conjugated
donkey anti-mouse IgG (1:500, Life Technologies, A21203) for visualization. This
antibody targets the IL-6 cytokine which is produced by cardiomyocytes, macrophages and
adipose tissue.
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C) Isolectin Conjugate: Isolectin GS-IB4 Alexa Fluor 488 Conjugate (1:100 Life
Technologies, I21411) was used to stain the endothelial cells. This conjugate is composed
of the Isolectin IB4 glycoprotein which is a part of the five tetrameric lectin family and
targets -D-galactosyl residues on cell membranes. This conjugate labels the endothelial
cells which are in the inner wall of the vasculature (microvasculature and
macrovasculature), and also labels murine macrophages and laminin.
D) CD36: Rabbit Polyclonal anti-CD36 antibody (1:250, Novus Biologicals, NB400-144)
was used along with using Alexa Fluor-594 conjugated donkey anti-rabbit IgG (1:500, Life
Technologies, A21206). This antibody marks the leukocyte differentiation antigen, CD36
which is found in the tissues that are involved in lipid metabolism such as adipocytes,
microvascular endothelial cells and cardiomyocytes.
E) Nuclei were visualized with DAPI Prolong Diamond mountant (Thermo Fisher
Scientific, P36962).

To capture the background autofluorescent staining in the images, tissue sections were
incubated only with the secondary antibodies (Alexa Fluor-594 conjugated donkey antirabbit IgG, Fluor-594 conjugated donkey anti-mouse IgG, Alexa Fluor-594 conjugated
donkey anti-rat IgG and Alexa Fluor-488 conjugated donkey-anti-mouse IgG).

2.6.3 Confocal Microscopy
2.6.3.1 Image acquisition
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Sections were imaged on a confocal microscope (Nikon A1 R Canada) equipped with NIS
Elements AIR 5.02.00 software using a 60x oil-immersion objective. The microscope was
equipped with four lasers: DAPI (405nm), FITC (490nm-519nm), TRITC (561nm-594nm)
and Cy5 (633-647nm), and they were switched on separately to reduce the cross-talk
between the fluorochromes. Five sections were imaged per cardiac tissue and for each
section, five regions of interest (ROIs) were captured. To visualize the microvasculature,
the Nyquist option of image capturing was used to capture the field of interest and then
image acquisition was done by higher pixel resolution (1024). To visualize the large
vessels, five sections were imaged per cardiac tissue, and ten ROIs within the vessel
structure were captured. To display the maximum contrast and brightness, images were
deconvoluted using the 2D deconvolution algorithm on NIS Elements AIR 5.02.00.

2.6.3.2 Image analysis
The analysis was done using the ROI statistic option of the NIS Elements AIR 5.02.00
software.

A) Fluorescence intensity analysis was conducted on the 5 ROIs from each section and
the intensity was normalized to the negative control (secondary antibody alone) as
described above. The fluorescence intensity analysis was done for Cy5-ghrelin (119), Cy3-des-acyl-ghrelin (1-19), F4-80, IL-6 and CD36.

B) The extent of colocalization was determined by using the colocalization analysis in
NIS Elements. This software generates a scatter plot of red and green
(representative of CD36 and isolectin), green and purple (representative of Isolectin
and GHSR), purple and red (representative of GHSR and IL-6, GHSR and F4-80)
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were used to determine the levels of correlation between each pair of markers.
Then, by using Coste’s algorithm the Pearson’s correlation coefficient (PCC) was
computed.

2.6.3.3 Statistical Analyses
Statistical analyses were conducted, and graphs were plotted using GraphPad Prism v.7.03
(San Diego, California, United States). T-Test was used to compare the levels of GHSR
between the DMD and age-matched WT using SPSS software v.24.0. A p value of <0.05
was considered significant. To correlate the level of inflammation with GHSR, linear
regression analysis was run on the F4-80 vs. GHSR data and also on IL-6 vs. GHSR data.

2.7 Cell Culture
For mechanistic studies, mouse cardiac microvascular endothelial cells (MCEC) were
purchased from Cedarlane (Burlington, Ontario, Canada). The MCECs were maintained in
Dulbecco’s Modified Eagle Medium (DMEM) (Life Technologies, 11960-044)
supplemented with 5% Newborn Calf Serum (NCBS) (Life Technologies, 16010142), 2
mM L-glutamine (Life Technologies, 25030081) and 100 units/mL penicillin-streptomycin
(Life Technologies, 15070063), at 37°C and 5% CO2. When MCECs reached 75-90%
confluency they were dissociated from the plate with 0.25% trypsin/EDTA (Thermo Fisher
Scientific,25200072) for 5 minutes at 37°C and 5% CO2 and then diluted in regular
supplemented DMEM. The collected cells were seeded in 100-mm dishes for western
blotting or on 60-mm tissue culture dishes containing glass coverslips for
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immunocytochemistry studies. Treatment with 10 ng/mL, 250 ng/mL and 500 ng/mL of
TNF-α (Abcam, ab9740) or vehicle control was performed in serum-free DMEM for 6, 16
and 24 hours.117

2.8 Immunocytochemistry and Immunofluorescence Microscopy
2.8.1 Immunostaining
At the end of each treatment, cells were fixed with 2% paraformaldehyde (PFA) (Electron
Microscopy Sciences, 15710-S) for 30 minutes at room temperature, permeabilized with
0.25% Triton-X100 for 5 minutes and blocked with 1% bovine serum albumin (BSA)
(Fisher Scientific, BP6711) in PBS for 1 hour at room temperature. The coverslips were
incubated with the primary antibody, mouse anti-ICAM-1 (Intercellular Adhesion
Molecule 1, 1:250, Abcam, ab171123), overnight at 4°C. Mouse anti-ICAM-1 targets the
glycoprotein on the cell surface of the endothelial cells. Upon cytokine stimulation, the
level of ICAM-1 increases in the endothelial cells.
To visualize ICAM-1, cells were incubated with the secondary antibodies, Alexa Fluor488 conjugated donkey anti-mouse IgG (1:500), for 2 hours at room temperature. Then,
cells were incubated with Cy5-ghrelin (1-19) (1:100) for 30 minutes to visualize GHSR.
Coverslips were mounted using the Prolong Diamond mountants with DAPI (Thermo
Fisher Scientific, P36962). As a negative control, cells were incubated with the secondary
antibodies alone.

2.8.2 Confocal Microscopy
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2.8.2.1 Image acquisition
Slides were imaged on a confocal microscope (Nikon A1 R Canada) equipped with NIS
Elements AR 5.02.00 software using a 60x oil-immersion objective. The microscope was
equipped with four lasers including DAPI (405nm), FITC (490nm -519nm), TRITC
(561nm-594nm) and Cy5 (633-647nm) and they were switched on separately to reduce the
crosstalk between the fluorochromes. Images were acquired from four slides per treatment
at five regions of interest (ROIs) per slide. To display the maximum contrast and brightness
in all images, the deconvolution algorithm on NIS Element AR 5.02.00 was applied in the
same manner to all images.

2.8.2.2 Image analysis
The analysis was done using the ROI statistic option of the NIS Element AR 5.02.00
software as described in Section 2.6.3.3. The fluorescence intensity analyses for GHSR
(Cy5-ghrelin (1-19)) and ICAM-1were conducted on the five ROIs from each slide and the
intensities were normalized to their negative control. Colocalization analysis generated a
scatter plot of green and red which represents the co-expression of ICAM-1 and GHSR.
Coste’s algorithm computed the Pearson’s correlation coefficient (PCC) as stated above.

2.8.2.3 Statistical Analyses
Statistical analyses were conducted, and graphs were plotted using GraphPad Prism v.7.03
(San Diego, California, United States). One-way ANOVA used to compare the levels of
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GHSR and ICAM between the treated and untreated cells with TNF-α on the means of four
technical replicates. A p value of <0.05 was considered significant.

2.9 Cell lysates & Immunoblotting
2.9.1 Western blotting
Cell lysates were prepared in radioimmunoprecipitation assay (RIPA) lysis buffer (Life
Technologies, 89900) containing proteinase inhibitor mini-EDTA (Sigma Aldrich,
11836153001). Protein content was quantified using a bicinchoninic acid (BCA) assay kit
(BioVision, K813-2500). Thirty μg of total protein were loaded in each lane and separated
on 4-12% NUPAGE gel (Invitrogen, NP0335). The resolved bands were transferred onto
polyvinylidene difluoride (PVDF) membranes (Life Technologies, IB401001) using the
iBlot® dry transfer system (Invitrogen). Membranes were blocked in 5% BSA in Trisbuffered saline-Tween (TBST) for 1 hour at room temperature. Then, membranes were
probed with primary antibodies including rabbit anti-GHSR (1:500, Santa Cruz
Biotechnology, sc-374515) and anti-beta-actin (1:1000, Abcam, ab199799) overnight at
4°C. Bands were visualized using secondary antibodies conjugated to horseradish
peroxidase (HRP): goat anti-rabbit HRP (1:1000, Invitrogen, PI31460) and goat antimouse HRP (1:1000, Abcam, ab6789). Bands were visualized with western ECL substrate
(Thermo Fisher Scientific, 32106).

2.9.2 Image acquisition and analysis
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Membranes were imaged using a BioRad ChemiDoc Imaging System. Band intensities
were determined by ImageJ FIJI version 1.46 (National Institute of Health, Maryland,
United States) and normalized to the beta-actin band intensities. The values were
statistically compared using one-way ANOVA. Densitometry units are displayed as mean
± SEM and a p-value of <0.05 was considered significant.
Table 1. Antibodies used for immunofluorescence microscopy.

Antibodies

Source

Dilution Target

Catalog

Research
Resource
Identification
number

Rat F4-80

Abcam

1:200

F4-80

ab16911

AB-443548

ab9324

AB-307175

glycoprotein
Mouse IL-6

Abcam

1:100

IL-6
Cytokine

Rabbit

Novus

CD36

Biologicals

Mouse

Abcam

1:250

CD36

NB400-144 AB-10003498

antigen
1:250

ICAM-1

ICAM-1

ab171123

glycoprotein

Rabbit

Santa Cruz

GHSR

Biotechnology

1:500

GHSR

sc-374515

AB-10987651
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Rabbit Beta-

AB-2305186

Abcam

1:1000

Beta-actin

Ab8227

Isolectin

Life

1:100

Endothelial

I21411

AB-2314662

GS-IB4

Technologies

1:500

A21209

AB-2535795

1:500

A21203

AB-141633

actin

cells

Alexa Fluor
488
Conjugate
Alexa Fluor-

Life

594

Technologies

conjugated
donkey antiRat IgG
Alexa Fluor-

Life

594

Technologies

conjugated
donkey antimouse IgG
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Chapter 3
3

Results

3.1 Characterization of cardiac tissue pathology in the DMD heart

I characterized the cardiac tissue pathology in wild-type and dmd (mdx:utrn-/-) cardiac
tissues stained with hematoxylin and eosin (H&E) and Masson’s trichrome. For each slide,
the entire tissue section of the myocardium in WT and DMD mice was screened to
determine the full extent of degeneration and fibrosis. The left ventricular myocardium of
DMD mice was mainly affected, so analysis focused on this region. We first compared the
cellular organization between WT and DMD mice at 15-17 weeks of age (Figure 3).
In WT mice, cardiac muscle fibers were organized and had a cross-striation that provides
the three-dimensional network connected by intercalated disks (Figure 3 panels A and B).
Cardiomyocytes were either mononucleated or binucleated with a central nucleus in the
extensive pinkish-red cytoplasm (Figure 3, panel C) In contrast, cardiac myofibers in
DMD mice were shrunken, had lost their nuclei and striation, and stained palely with eosin
(Figure 3 panel F). Vacuoles were also found within the cardiomyocyte sarcoplasm and
could be a manifestation of myofiber necrosis and cardiomyopathy (Figure 3 panel E).
Pyknotic nuclei and aggregation of lymphocytes indicate the necrosis and chronic
inflammation within the myocardium of the DMD mice (Figure 3 panel E). Our findings
illustrate that the pathology of cardio muscular dystrophy in DMD mice includes pyknosis
(black arrow), lymphocytic infiltration (green arrow), vacuolization (red arrow).
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Figure 3. Representative images of cardiac tissue architecture of the left ventricle in
wild-type and DMD (mdx:utrn-/-) mice at 15-17 weeks of age(n=3).
Cardiac tissue sections were stained with Hematoxylin and Eosin (H&E) and images were
acquired at 10x, 20x and 40x magnification of the myocardium of the left ventricle in wildtype (top row) and DMD (bottom row) mice. (B), Cardiac muscle fibers form the
interconnecting three-dimensional network. (C), Cardiac muscle cells contain one or two
nuclei which are centrally located with extensive eosinophilic cytoplasm; healthy cardiac
fibers have regular cytoplasmic cross-striations. (E), Cardiac myofibers in DMD mice are
loose without cross-striation. The red arrow indicates cardiomyocyte vacuolation that is a
marker of cardiac degeneration. (F), The size of nuclei in the cardiomyocytes is variable.
The black arrows show the shrunken myocyte and pyknosis in the myocardium. Yellow
and green arrows indicate a fibroblast and lymphocyte aggregates, respectively. Boxes
represent the magnified areas.
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To determine the extents of both cardiac tissue degeneration and fibrosis simultaneously,
we aligned the H & E and Masson’s trichrome staining in the same area of the cardiac
tissue. To determine the level of fibrosis in the wild-type and DMD mice, Masson’s
trichrome staining was performed to visualize the collagen content in the myocardium. The
myocardium stained red while the collagen content was blue. We compared tissue
morphology/architecture with the extent of fibrosis. In WT mice, cardiac myofibers in the
lateral wall of the LV were uniformly red, organized and didn’t have any collagen staining
(Figure 4, bottom row). In contrast, there was a significant amount of fibrosis in the lateral
wall of the left ventricle in DMD mice (Figure 5, panel D). There were pyknotic nuclei
and lymphocyte infiltration above the collagen fibers (Figure 5, panels C and F).
Fibroblasts, which are the elongated (spindle-shaped) cells, were located adjacent to the
collagen fibers (Figure 5, panel F).
I also investigated the extent of fibrosis in the LV apex of DMD mice (Figure 6). At 10X
magnification, the loss of organized architecture of myofibers was visualized, and there
was a large extent of collagen and fat deposition in this area (Figure 6, panels A and D).
At a higher magnification, pyknotic nuclei and aggregation of lymphocytes were seen
(Figure 6, panels C and F), indicating cardiomyocyte necrosis and chronic inflammation,
respectively. There are also large areas of adipose tissue and collagen deposition in the LV
apex of the DMD myocardium that surround disorganized and degenerated myofibers
(Figure 6, panel F).
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Figure 4. Representative histology images of the left ventricle in wild-type cardiac
tissue (n=3). Architecture of the heart in WT mice with 10x, 20x and 40x magnifications.
(A, B, C) H&E staining of left ventricle myocardium in WT mice. Myocardial fibers are
organized and have normal striation. The cardiomyocytes are either mononucleated or
binucleated which are blue in color and centrally located. (D, E, F) Masson’s Trichrome
staining of left ventricle myocardium in wild-type mice. The cardiac muscle is bright red
and there is no collagen content (blue staining) in the wild-type myocardium. (Boxes
represent the magnified area)
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Figure 5. Representative histology images of the left ventricle in DMD (mdx:utrn-/-)
mice (n=3). (A, B, C) H&E staining at 10x, 20x and 40x magnification, respectively.
Myocardial fibers are disorganized and have irregular striation. The cardiomyocytes’
nuclei are acentric and variable in size. The black arrow indicates an area of pyknotic
nuclei, and the green arrow points to lymphocytes. (D, E, F) Masson’s trichrome staining;
the panels align with the H&E staining above. (D), The diffuse pattern of collagen
deposition in the DMD heart. (E), Cardiac myofibers show a loss of striation around an
area of collagen deposition. (F), The size of nuclei in the cardiomyocytes is variable. The
yellow arrows indicate fibroblasts adjacent to the area of collagen deposition. Boxes
represent the magnified areas. Panels A and D are not completely aligned due to the blue
artifacts in Masson’s Trichrome staining.
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Figure 6. Representative histology images of the left ventricular apex in DMD
(mdx:utrn-/-) mice(n=3). (A, B, C) H&E staining at 10x, 20x and 40x magnification,
respectively. High magnification in panel C reveals the disruption in myocardial tissue
organization, leukocyte infiltration, adipose tissue deposition (blue arrow) and neurons
(yellow arrow). (D, E, F) Masson’s trichrome staining. These panels align with the H&E
staining above. (E) There is diffuse fibrosis (blue) and cardiac tissue stains pale red. (F)
The blue arrow indicates the adipose tissue in the myocardium and the adjacent myofibers
are degenerated. (F) Yellow and blue arrows indicate neurons and adipose tissue,
respectively. Boxes represent the magnified areas.
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3.2 GHSR in cardiac tissue

Our lab has previously shown that GHSR may be a biomarker of heart failure in humans
114

and also a biomarker of diabetic cardiomyopathy in mice 113. The next set of experiments

investigated if GHSR was present in the microvasculature of the heart, and how GHSR
levels are altered with levels of inflammation during the progression of dilated
cardiomyopathy in DMD mice.
I stained the cardiac tissues with Cy5-ghrelin (1-19) along with AlexaFluor488-isolectin to
evaluate the presence of GHSR in the microvasculature within the myocardium of WT and
DMD mice. GHSR is present at very low levels in WT cardiomyocytes and is significantly
elevated (p<0.0001) in DMD heart (Figure 7A and B). Microvessels in the myocardium
of WT demonstrated an organized and cylindrical shape. The expression of GHSR was not
seen in the microvessels since there was no colocalization between the isolectin and Cy5ghrelin (1-19) binding (Figure 7A). In DMD mice, the cylindrical architecture of the
microvessels in the left ventricle appeared to be disrupted, and there was also no
colocalization between isolectin and Cy5-ghrelin (1-19) (Figure7A). Therefore, GHSR
does not appear to be present in the cardiac microvasculature in either WT or DMD mice.
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Figure 7. GHSR expression is elevated in DMD cardiac tissue. (A) Representative
fluorescent images of the left ventricle in wild-type and DMD mice (mdx:utrn-/-). The
cardiac tissues were stained with Cy5-ghrelin (1-19) and isolectin to show GHSR (purple)
and microvessels (green), respectively. Nuclei were visualized with DAPI (blue). Cardiac
microvasculature in the DMD heart looks aberrant and have an irregular shape; whereas,
in wildtype, microvasculature has the normal circular shape. (B) GHSR fluorescence
intensity is elevated in DMD mice (n=3, ****p<0.0001). Data are represented as mean
fluorescence intensity ± SEM. Each bar represents fluorescence intensities from 5 ROIs
from each of 5 sections per heart.

3.3 Correlation between LVEF and GHSR
Our previous results have shown a negative correlation between GHSR and Left
Ventricular Ejection Fraction (LVEF) in patients who underwent cardiac transplantation.114
As well, previous work from Dr. Hoffman’s group has shown the development of dilated
cardiomyopathy in DMD mice at 15 weeks of age.59 In that study, they performed microCT and echocardiography on wild-type and DMD mice to measure LVEF and showed that
DMD mice had significantly decreased LVEF compared to WT mice.
To more closely examine the relationship between GHSR and cardiac dysfunction, I
performed linear regression analysis on the previously reported LVEF values and Cy5ghrelin (1-19) fluorescence intensities from the same WT and DMD mice in the present
study. There is a strong inverse correlation between LVEF and myocardial GHSR
expression (*p<0.05, r = -0.863). (Figure 8).
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Figure 8. Correlation between ejection fraction (%) and the level of GHSR in
cardiac tissues in WT and DMD mice. There is a significant inverse correlation
between the ejection fraction and Cy5-ghrelin (1-19) fluorescence intensity in the DMD
cardiac tissue. Each data point represents values from one mouse.
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3.4 Levels of GHSR correlate with levels of inflammatory markers
To investigate the relationship between GHSR and inflammation, I stained the cardiac
tissues with the macrophage marker F4-80 together with Cy5-ghrelin (1-19) and Alexa
Fluor 488-isolectin. In WT myocardium, there is low expression of GHSR and no
detectable expression of F4-80. AlexaFluor488-isolectin marked the cardiac microvessels
in WT myocardium (Figure 9A, top panels). In contrast, there were markedly higher
levels of F4-80 and Cy5-ghrelin (1-19) binding in the left ventricular tissue from DMD
mice (Figure 9A, bottom panels), both of which were significantly different (p<0.0001)
from WT (Figure 9B). Levels of F4-80 and Cy5-ghrelin (1-19) were strongly correlated
(R2 = 0.97, p<0.004, Figure 9B). There were also higher levels of AlexaFluor488-isolectin
fluorescence in the DMD myocardium (Figure 9A). Upon high-resolution imaging (Figure
10), the fluorescent signals from AlexaFluor488-isolectin and F4-80 overlapped within
discrete areas; therefore, AlexaFluor488-isolectin was also labeling macrophages in the
DMD myocardium. As well, there was overlap with Cy5-ghrelin (1-19), suggesting that
GHSR may be expressed in the cardiac macrophages in DMD myocardium (Figure 10).
The identification of macrophages in the cardiac tissue from DMD mice at 15-17 weeks of
age indicates chronic inflammation in the DMD myocardium.
Pearson’s correlation coefficient of 0.926 between GHSR vs. F4-80 and of 0.784 between
isolectin vs. F4-80 indicates colocalization between GHSR and macrophage marker and
between the isolectin and the macrophage marker.
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Figure 9. GHSR colocalizes with the macrophage marker F4-80. (A) Representative
fluorescent images of the left ventricle in wild-type and DMD (mdx:utrn-/-) mice show
Cy5-ghrelin(1-19), F4-80 and isolectin staining to visualize GHSR (purple), macrophages
(red) and the vasculature (green), respectively. Nuclei are visualized with DAPI. (B)
Quantification of fluorescence intensities for Cy5-ghrelin (1-19) (n=3, ****p<0.0001) and
F4-80 (n=3, ****p<0.0001). Data are represented as mean fluorescent intensity ±SEM.
Each bar represents fluorescence intensities from 5 ROIs from each of 5 sections per heart.
Linear regression analysis indicates a strong correlation between GHSR and F4-80
(****p<0.0004, R2 =0.9669).

To examine further the relationship between GHSR and inflammation within the
myocardium of the left ventricle in DMD mice, I assessed levels of the pro-inflammatory
cytokine IL-6, along with Cy5-ghrelin (1-19) and isolectin (Figure 11A). Interestingly, IL6 expression was also seen in the lumen of the microvessels in the DMD mice, which might
be an indicator of monocytes in the lumen, further indicating the extent of inflammation in
the left ventricle of DMD mice (Figure 11A, arrows). Quantification of fluorescence
intensities showed that IL-6 expression levels were significantly greater in DMD
myocardium (****p<0.0001) and GHSR was also elevated in DMD (****p<0.0001)
(Figure 11B). There was a strong correlation (***p<0.002, R2 =0.9286) between GHSR
and IL-6. (Figure 11-B).
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Figure 10. GHSR is expressed in cardiac macrophages. The ROI indicated in the top
panel was subject to Nyquist analysis to increase the resolution. Cardiac tissues from DMD
mice were stained with Cy5-ghrelin (1-19), F4-80 and isolectin to visualize the GHSR
(purple), macrophages (red) and the vasculature (green), respectively. Nuclei were
visualized with DAPI. White color indicates the colocalization of the three signals (red,
green and purple) which indicates the presence of GHSR in cardiac macrophages (arrows).
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Figure 11. GHSR and the pro-inflammatory cytokine IL-6 are increased in cardiac
tissue from DMD mice. (A) Representative confocal fluorescence images of the left
ventricular myocardium in WT and DMD (mdx:utrn-/-) mice. Cardiac tissues were stained
with Cy5-ghrelin (1-19), IL-6 and AlexaFluor488-isolectin to visualize GHSR, IL-6
cytokine and the microvessels, respectively. Nuclei were visualized with DAPI. The arrows
indicate the cardiac microvessels of WT mice (top row) and IL-6 staining within the
microvessels in DMD myocardium (bottom row). (B) Quantification of fluorescence
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intensities for GHSR (n=3, ****p<0.0001) and IL-6 (n=3, ****p<0.0001). Data are
represented as mean fluorescent intensity ±SEM; each bar represents fluorescence
intensities from 5 ROIs from each of 5 sections per heart. Linear regression analysis
indicates a strong positive correlation for the GHSR vs IL-6 in the cardiac tissues
(***p<0.002, R2 =0.9286).

3.5 GHSR and des-acyl-ghrelin binding in the large cardiac blood
vessels.
My results revealed that there is no GHSR in the cardiac microvasculature. Therefore, I
asked if the GHSR exists in the large vessels in the heart. Since there is scarce information
regarding the binding of des-acyl ghrelin in heart, I co-stained the cardiac tissues with Cy5ghrelin (1-19) and Cy3-des-acyl- ghrelin (1-19) to determine the binding sites in the large
vessels of the vasculature. Interestingly, there was very little to no fluorescence signal in
the vasculature (as determined by AlexaFluor488-isolectin staining) of WT mice. In
contrast, there was detectable GHSR and des-acyl-ghrelin binding in the DMD cardiac
macrovessels. (Figure 12A). Quantitative analysis of fluorescence intensities showed that
the expression of GHSR (p<0.0001) and binding of Cy3-des-acyl-ghrelin (p<0.001) were
both significantly higher within the cardiac microvasculature of DMD mice. (Figure 12B).
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Figure 12. GHSR and Des-acyl-ghrelin in large vessels in cardiac tissues. (A)
Representative fluorescence confocal microscopy images of large vessels in cardiac tissue
of wild-type and DMD (mdx:utrn-/-) mice. The cardiac tissues were stained with Cy5ghrelin (1-19), Cy3-des-acyl ghrelin (1-19) and AlexaFluor488-isolectin to visualize
GHSR, des-acyl-ghrelin binding and the large vessels, respectively. Nuclei were visualized
with DAPI. Arrows indicate the large vessel in the cardiac tissues. (B) Quantification of
fluorescence intensities for Cy5-ghrelin (1-19) (n=3, ****p<0.0001) and Cy3-des-acylghrelin (1-19) (n=3, ***p<0.001). Each bar represents fluorescence intensities from 10
ROIs within the vessel structure from each of 5 sections per heart. Data are represented as
mean fluorescent intensity ± SEM.

3.6 CD36 in Cardiac tissues
The fatty acid transporter, CD36, is also present on microvascular endothelial cells. There
is evidence that CD36 is upregulated in cardiac contractile dysfunction118. I assessed the
presence of CD36 in myocardial tissue and vasculature in WT and DMD mice. CD36 was
present in the microvascular endothelial cells in WT cardiac tissue as assessed by colocalization with AlexaFluor488-isolectin (Figure 13A, top row). In DMD mice, the
pattern of CD36 expression was more widely distributed throughout the tissue in structures
that were both isolectin-positive and -negative (Figure 13A, bottom row). Quantitative
analysis of fluorescence intensities showed that CD36 was present at significantly higher
levels in DMD cardiac tissue (p<0.001) (Figure 13B).

52

***p< 0.001
1000

800

600

400

200

D

T

0

D

M

W

B

M e a n F lu r o r e c e n c e In te n s ity (A U )

A

C D 36

Mean values+S.E.M (n=3)

53

Figure 13. CD36 levels in the left ventricular myocardium. (A) Representative
fluorescent images of left ventricular myocardium in WT and DMD (mdx:utrn-/-) mice.
The cardiac tissues were stained with Cy5-ghrelin (1-19), CD36 and AlexaFluor488isolectin to visualize GHSR, CD36 and the vasculature, respectively. Nuclei were
visualized with DAPI. The CD36 expression is elevated in DMD in microvessels and in
other structures which might indicate adipose tissue deposition in the myocardium of DMD
mice. (B) Quantification of the fluorescence intensity for CD36 in the WT and DMD
cardiac tissues. Each bar represents fluorescence intensities from 5 ROIs from each of 5
sections per heart. Data are represented as mean fluorescent intensity ± SEM (n=3,
***p<0.001)

3.7 The effect of the pro-inflammatory cytokine TNF on GHSR
expression in murine cardiac microvascular endothelial cells

To further investigate the connection between GHSR and vascular inflammation, I used
cardiac microvascular endothelial cells (MCEC)s that were cultured to confluency and
treated with increasing concentrations of TNF-α. Cells were then assessed for GHSR by
western blot analysis (Figure 14A). Densitometric analysis of the GHSR-immunoreactive
bands indicates that a dose of 500 ng/mL of TNF induces the highest level of GHSR in
MCECs (Figure 14B). GHSR levels increased 4.5X upon treatment with 250 ng/ml TNFα (p<0.05), and over 15X upon treatment with 500 ng/ml TNF-α (p<0.001), indicating that
GHSR is up-regulated in response to a pro-inflammatory stimulus.
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Figure 14. GHSR increases upon treatment of MCECs with the pro-inflammatory
cytokine TNF-α. (A) Cardiac Microvascular Endothelial Cells (MCEC)s were treated
with 10, 250 or 500 ng of TNF- for 16 hours. Cell lysates were collected, and proteins
were separated on a 4-12% NUPAGE gel. Membranes were immunoblotted for GHSR
and beta-actin. (B) Densitometric analysis of GHSR normalized to -actin. Data are
represented as mean ±SEM and one-way ANOVA was performed on the average of n=4
separate experiments. *p < 0.05; ***p < 0.001.

To visualize changes in GHSR levels and distribution within MCECs after cytokine
stimulation, cells were cultured to confluency, treated with 10, 250 or 500 ng/mL of TNFα for 16 hours and stained with Cy5-ghrelin (1-19) and DAPI (Figure 15A). GHSR
expression in MCECs is more cytoplasmic and the level of expression escalated in a dosedependent manner. 500 ng/mL treatment induced the highest level of GHSR in MCECs (p
< 0.0001). (Figure 15B).
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Figure 15. The level of GHSR increases with cytokine-induced inflammation in
cardiac microvascular endothelial cells. (A) Representative fluorescence images from
MCECs that were treated with 10, 250 or 500 ng of TNF- for 16 hours, fixed and stained
with Cy5-ghrelin (1-19) and DAPI to denote GHSR and nuclei. (B) Quantification of the
fluorescence intensity of Cy5-ghrelin (1-19). Each bar represents fluorescence intensities
from 5 ROIs from each of 4 coverslips per treatment. Data represent the mean fluorescent
intensity ±SEM and a one-way ANOVA was performed on the average of N=4 separate
experiments. **p = 0.0058; ****p < 0.0001; ****p < 0.0001

Upon cytokine stimulation, the level of ICAM increases in the endothelial cells. It is known
that TNF-α increases expression of ICAM-1 through the NF-B pathway and ICAM-1
promotes leukocyte adhesion and increases vascular permeability.119

120

My results

indicated a dose-dependent increase of GHSR in MCECs treated with TNF-α. My question
was whether the increase in GHSR occurred in parallel with an increase in ICAM-1. To
answer this question, I treated MCECs with TNF-α and co-stained MCECs for ICAM-1
(green) and with Cy5-ghrelin (1-19) (red). Both GHSR and ICAM-1 appeared as diffuse
intracellular signals in MCECs (Figure 16A). Both GHSR and ICAM-1 expression
increased in a dose-dependent manner (Figure 16B). However, there was no significant
colocalization between GHSR and ICAM-1 in MCECs as assessed by Pearson correlation
coefficient. (Figure 16C).
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Figure 16. GHSR does not colocalize with the ICAM in MCECs treated with TNF-
(A) Representative fluorescence images from MCECs that were treated with 10, 250 or
500 ng/mL of TNF- for 16 hours, fixed and permeabilized, and stained with Cy5ghrelin(1-19), and for ICAM-1 and DAPI. (B) Quantification of the fluorescence
intensities of Cy5-ghrelin (1-19) and ICAM-1. Each bar represents fluorescence
intensities from 5 ROIs from each of 4 coverslips per treatment. Data represent the mean
fluorescent intensity ±SEM and a one-way ANOVA was performed on the average of
N=4 separate experiments (ICAM: **p = 0.0013; ****p < 0.002; ****p < 0.0001);
(GHSR: **p = 0.0058; ****p < 0.0005; ****p < 0.0001) (C) Pearson’s correlation
coefficient (PCC) indicate statistic colocalization between the ICAM-1 and Cy5-ghrelin
(1-19). Data are represented as average PCC values ±SEM.*p< 0.01, N=4 separate
experiments.
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Chapter 4

4 Discussion & Future Direction

DMD is an X-linked disease that results from the loss of dystrophin and leads to the
development of dilated cardiomyopathy resulting from inflammation, cardiomyocyte
death, and fibrosis. Since 90% of DMD patients die due to heart failure, there is an
emerging need to understand the cardiac manifestation of DMD. To date, there is no cure
for DMD and most therapies for dilated cardiomyopathy have not been successful. For a
more beneficial therapy, we need to diagnose dilated cardiomyopathy at an early stage.
Identification of tissue-specific biomarkers could open new doors for targeted therapies. In
the work described in this thesis, I sought to characterize the cardiac pathology in a mouse
model of DMD, mdx:utrn-/-, and to investigate whether GHSR could be a biomarker for
DMD dilated cardiomyopathy.
Briefly, the main objectives were: 1. To characterize GHSR and inflammatory markers in
cardiac tissues in a mouse model of DMD; and 2. To characterize GHSR in vascular
endothelial cells and determine its correlation with the level of inflammation.

4.1 Characterization of cardiac tissue pathology in the mdx:utrn-/- mouse
This is the first study that has evaluated the extent of cardiac degeneration in mdx:utrn-/mice via histological techniques. Studies from our lab had previously measured functional
changes during the development of dilated cardiomyopathy in vivo in the mdx:utrn-/mouse model at 15-17 weeks of age with micro-CT and echocardiography.
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histopathology of the skeletal muscle, but not the cardiac muscle, has been previously
characterized by other research groups, including our group.121

122 123 124

In this study, I

focused more on examining the left ventricle of DMD mice since in DCM, the left ventricle
is mainly affected and also cardiac MRI has confirmed the particular involvement of the
left ventricle in DMD patients. 21 125
The gold standard histopathology staining, H&E, for mdx:utrn-/- mice detailed the extent
of chronic inflammation in cardiac tissues at 15-17 weeks of age. It showed the existence
of lymphocyte aggregates in the lateral wall and apex of the left ventricle that is a hallmark
of chronic inflammation. Pyknosis is a feature of myocardial necrosis which is sparse and
more focal in mdx:utrn-/- mice, and it triggers macrophage migration to the site of tissue
damage and cell death.76 126
Cardiomyocyte vacuolation also presents in these mice which is another feature of
myofiber necrosis and cardiomyopathy. Electron microscopy has shown that the
vacuolization occurs due to damage in mitochondria or smooth endoplasmic reticulum
(SER) which leads to sarcolemmal swelling and necrosis. The mechanism of the
mitochondrial or SER damage is poorly understood but it may occur due to impairments
in the ATP-dependent ion pump in the mitochondrial and SER membranes.127

128

Cardiomyocyte vacuolization may also be the result of impaired blood flow associated with
endothelial dysfunction and ischemia.129
Fat deposition or lipomatosis in the DMD myocardium is a hallmark of chronic
cardiomyopathy. Adipose tissue infiltration interferes with the intercalated disks that allow
for synchronization of cardiomyocyte beating leading to arrhythmias and causing sudden
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death. However, the mechanism by which adipose tissue forms and get stored in
cardiomyopathy remains unknown. 45 130
Fibrosis in the myocardium was detected in the left ventricle by Masson’s Trichrome
staining. Fibroblasts form a fibrocollagenous scar tissue replacing cardiomyocytes, thereby
impairing myocardial contraction. This myocardial fibrosis in the mdx:utrn-/- mice was
very diffuse, and there was more collagen deposition in the apex compared to the lateral
wall of the left ventricle. This fibrotic pattern is very similar to what is seen in DMD
patients and it is unique to dystrophinopathies. 30 131

4.2 GHSR is elevated in myocardium of the mdx:utrn-/- mouse
Having characterized the morphological changes of dilated cardiomyopathy in the
mdx:utrn-/-mouse model, I investigated whether myocardial GHSR levels are altered in our
model as assessed by the binding of our imaging probe, Cy5-ghrelin(1-19). With using this
fluorescent peptide analog of ghrelin, our lab has previously shown that GHSR levels are
altered before and after cardiac transplantation in humans,
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and also in diabetic

cardiomyopathy in mice .113 My results showed an elevation in GHSR in the myocardium
of the mdx:utrn-/- mice at end-stage cardiomyopathy, which is in agreement with the
elevated levels of GHSR that our lab has reported in end-stage human heart failure.114
However, my results are in contrast with the mouse diabetic cardiomyopathy studies, where
the level of GHSR is down-regulated using both fluorescence microscopy with Cy5ghrelin(1-19) and Western blot analysis.113 The reason for this discrepancy between the
mice with diabetic cardiomyopathy and the mdx:utrn-/- mice could be possibly explained
by the fact that they were in different stages of cardiac disease. Diabetic cardiomyopathy
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mouse model showed very mild changes in heart function and no sign of inflammation or
fibrosis. In contrast, the mdx:utrn-/- mice had late-stage cardiomyopathy, with a highly
fibrotic and inflammatory pathology. Therefore, I suggest that GHSR is elevated in latestage cardiomyopathy, and down-regulated in early stage cardiomyopathy in mice.

4.3 Correlation between left ventricular function, cardiac pathology and
GHSR
The functional features of dilated cardiomyopathy are an increase in left ventricular volume
and decrease in EF.62 Previously, echocardiography and micro-CT had been performed on
my experimental mice to show that LVEF was decreased.59 This decline in LVEF in DMD
mice may also result in the severe pathology of the LV apex detailed in my study. It has
been proposed that the apex of the heart may be the most susceptible region of the heart
for thrombus formation due to lowered blood flow, which occurs in dilated
cardiomyopathy. To this end, there are reports on apical thrombus in DCM- affected
subjects which support this probable mechanism. 132 133 134
My data showed a negative correlation between GHSR levels and LVEF. These results
support our recent findings, which also demonstrated a negative correlation between the
LVEF and GHSR levels in patients who underwent cardiac transplantation.114 I speculate
that the elevated levels of GHSR in end-stage cardiomyopathy may be due to abnormal
signaling of pro-survival pathways in response to cardiomyocyte damage, necrosis and
apoptosis. These results suggest that GHSR may be an effective biomarker of LV function
in DMD cardiomyopathy.
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4.4 Chronic inflammation correlates with GHSR in DMD left ventricle
This study is the first of its kind to correlate levels of GHSR with cardiac inflammation, as
detected by macrophage infiltration and tissue cytokines. A notable feature of chronic
inflammation is the existence of lymphocytes and macrophages. Since H&E staining
cannot differentiate between lymphocytes and macrophages, we used fluorescence
immunostaining using F4-80 as a macrophage marker to detect the existence of
macrophages in the DMD myocardium. In chronic inflammation, both M1 (proinflammatory) and M2 (regeneration) macrophages are present.135 However, F4-80 cannot
differentiate between M1 and M2 macrophages. To evaluate the macrophage phenotypic
distribution, we need to use CD11c for M1 and CD206 as a marker of M2.136 Macrophages
implements a range of important immunoregulatory and inflammatory functions by
secreting chemokines and cytokines and also by degrading the extracellular matrix that
surrounds cardiomyocytes. Damaged cardiomyocytes activate pro-inflammatory signaling
pathways through NF-B which upregulates the production of pro-inflammatory cytokines
such as TNF-α, IL-1 and IL-6. As well, the Toll-like receptor (TLR) family also plays an
important role in tissue inflammation and cell death. Specifically, TLR4 was shown to be
involved in DMD pathogenesis, as TLR4 genetic ablation in mdx mice resulted in dramatic
blunting of macrophages, reduced fibrogenesis and increased capacity of skeletal muscle
regeneration. 137. TLR4 could be one of the key mediators in dilated cardiomyopathy since
it initiates cytokine activation in damaged cardiomyocytes.138 Therefore, the dilated
cardiomyopathy of DMD is highly inflammatory, and this process is mediated by both
macrophages and cardiomyocytes.
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My study has shown for the first time that GHSR is expressed in DMD murine
macrophages in the myocardium. The expression of GHSR in macrophages may indicate
a new role for ghrelin/GHSR in inflammation. A study showed that GHSR ablation in aged
mice reduced the macrophage infiltrates and also promoted the macrophage phenotypical
shift towards M2 (anti-inflammatory phase).139 As well, GHSR is present and elevated in
alveolar macrophages during sepsis-induced acute respiratory distress syndrome in rats, 140
and ghrelin administration inhibited GHSR signaling through the Wnt/β-catenin pathway,
reducing apoptosis and inflammation.
My studies show an increase in the expression of the cytokine IL-6 in the cardiac tissue of
DMD mice. These results are in agreement with the literature, which shows high levels of
IL-6 in the serum and inflammatory infiltrates of DMD patients. There is evidence that IL6 is elevated in the diaphragm muscle of mdx mice.141 142 In the heart, IL-6 has dual roles
in both cardioprotection and cardiac failure. In acute inflammation, IL-6 participates in
neurogenesis and wound healing and maintains cardiac integrity. In contrast, in chronic
inflammation, IL-6 activates constant signaling through the NF-kB pathway which leads
to fibrosis.143 My results suggest that the elevated levels of IL-6 are due to chronic
inflammation that will eventually lead to heart failure. There is a strong correlation between
IL-6 and GHSR in DMD which indicate GHSR involvement in inflammation. This data
may suggest that in inflammatory condition, GHSR is elevated to prevent apoptosis
through PI3K and ERK1/2 pathway and also promote cell proliferation through PI3K and
AKT pathway.
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4.5 GHSR and des-acyl-ghrelin binding sites in the cardiac vasculature
My studies showed that there is no GHSR expression in cardiac microvasculature in both
WT and DMD mice. I also showed that the arrangement of the microvasculature is
aberrant in the DMD myocardium, which may cause left ventricle microinfarct which
leads to necrosis. 77 144 However, the interpretation of these findings are limited, as
AlexaFluor488-isolectin marked the microvasculature in WT mice, but was not specific
to the vasculature in DMD mice, and also stained the murine macrophages.
My results showed that there is binding of both Cy5-ghrelin (1-19) and Cy3-des-acyl
ghrelin (1-19) in the cardiac macrovasculature, but not the microvasculature, in the DMD
mouse. No binding of either probe was evident in the large vessels of WT mice. In contrast
to Cy5-ghrelin (1-19), the binding of Cy3-des-acyl ghrelin (1-19) was observed only in the
large blood vessels, and not in cardiomyocytes. Its colocalization with isolectin in the
vessel wall, but not in cells within the lumen of the vessel, suggests that des-acyl ghrelin
binding sites are on endothelial cells.112 The elevated ghrelin and des-acyl ghrelin binding
in the DMD mouse might be an indicator of inflammation within large cardiac vessels.
This is the first demonstration of both ghrelin and des-acyl-ghrelin binding in cardiac
vasculature. I was able to detect binding sites for both ghrelin and des-acyl ghrelin in the
same tissue due to our fluorescent ghrelin analogs which are very specific; Cy5-ghrelin (119) binds specifically to GHSR in the mouse myocardium whereas Cy3-des-acyl-ghrelin
(1-19) does not.112 Interestingly, it has been shown that des-acyl ghrelin inhibits cell death
in endothelial cells through ERK1/2 signaling, but the receptor remains unknown.97
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4.6 CD36 in Cardiac tissues
CD36 is a fatty acid transporter. Normally, CD36 marks the microvascular endothelial cells
in cardiac tissue, and under conditions of inflammation, CD36 is also expressed in
cardiomyocytes, which could be evidence of cardiac dysfunction.145 In the DMD cardiac
tissue, CD36 no longer appeared to be restricted to the microvasculature structure, which
had lost the cylindrical structure and appeared aberrant.144 Our histopathology showed
adipose tissue infiltration in DMD cardiac tissue; coupled with the observation of CD36
immunoreactivity in isolectin-negative structures. Therefore, I suggest that the increase in
CD36 may be due to this adipose tissue infiltration. It has been shown that CD36 increases
in age-induced cardiomyopathy in mice as it is a major regulator of cardiomyocyte fatty
acid uptake in cardiomyocytes.146 This finding suggests that the elevation in CD36 may
promote myocardial lipotoxicity in mdx:utrn-/- mice.

4.7 The effect of the pro-inflammatory TNF-α on GHSR expression in
murine cardiac microvascular endothelial cells
For preliminary mechanistic studies, I further explored the relationship between GHSR and
inflammation in murine cardiac microvascular endothelial cells (MCECs). My experiments
revealed that there is an expression of GHSR in MCECs and it is elevated upon exposure
to the pro-inflammatory cytokine TNF- in a dose-dependent manner. These results are
consistent with my animal studies that showed a positive correlation between GHSR and
the pro-inflammatory cytokine IL-6 and the macrophage marker F4-80. However, there is
a discrepancy, in that I found GHSR to be present in the large vessels of cardiac tissues
under conditions of chronic inflammation, but not in the microvasculature. This apparent
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discrepancy may be due to the fact that MCECs is an immortalized neonatal cell line, and
the mouse tissues I used in this study, were from adult mice. Furthermore, to generate the
MCECs, cardiac microvascular endothelial cells had been transfected by lentiviral vectors
which carry the SV40 large T antigen and human telomerase. This cell line displays normal
characteristics of endothelial cells but through genetic modification, some cellular
functions may be altered and it’s a limitation for the cell studies. Therefore, GHSR
expression in the neonatal microvascular endothelial cell line, but not in adult mouse
cardiac microvascular endothelial cells, may indicate a role for ghrelin/GHSR in the
maturation of these cells from the neonatal to adult stage.
In endothelial cells, TNF-α increases expression of ICAM-1 through the NF-kB pathway
and ICAM-1 promotes leukocyte adhesion and increases vascular permeability.119
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ICAM-1 expression was also increased in a dose-dependent manner but it didn’t colocalize
strongly with GHSR in our model. The significance of these findings requires further
investigations.

4.8 Future Directions

We demonstrated that GHSR could be a biomarker for inflammation in dilated
cardiomyopathy in mdx:utrn-/- mice. To show the patterns in GHSR levels during the
development of DCM in this mouse model, we need to conduct the experiments outlined
in this thesis (correlation between inflammatory markers and GHSR) at earlier time points
such as 4-5 and 8-10 weeks of age. 4-5 weeks of age is a very early stage of DMD with no
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symptoms of cardiomyopathy; at 8-10 weeks of age, dilative cardiomyopathy is starting to
develop in mdx:utrn-/- mice.59
Future studies should introduce intravital microscopy along with the confocal microscopy
and measure the blood flow in DMD vasculature and compare it with WT. This study will
provide dynamic data on blood flow which could give more insight about DMD vasculature
and how ghrelin-derived therapeutics could affect or correct the vascular structure.147
Multiphoton laser scanning microscopy also could be used to study the DMD heart in
depth. This microscope enables us to do the 3D histology and in vivo imaging of the heart
with high-resolution and high-speed. With this microscope, we could visualize the beating
heart in vivo with subcellular resolution and we could study the migration of leukocytes
into the inflamed vasculature and cardiac tissue.148
For mechanistic studies to establish the relation of inflammation and GHSR in endothelial
cells, we need to silence GHSR through siRNA and determine how TNF-α induced
inflammation affects inflammatory signaling pathways (E-selectin, AKT, PI3K and VEcadherin) in endothelial cells by western blot, IF and ELISA.

To determine whether ghrelin has an anti-inflammatory effect on the endothelial cell, we
could treat the MCECs with hexarelin (a GHSR agonist which is more stable than ghrelin) at
different time points (30 min,70 min,6,24,48,72 hours) and determine the level of inflammation
by western blot, IF and ELISA.

Several studies demonstrated that ghrelin administration may improve skeletal muscle
mass and function in mdx mice .

149 150 151

In future studies, we could administer ghrelin

and des-acyl ghrelin to mdx:utrn-/- mice and measure the pro-inflammatory cytokines in
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plasma and also determine the level of GHSR and inflammatory markers in cardiac tissue
and vasculature. This will elucidate whether ghrelin could be used as a therapeutic for
DMD cardiomyopathy.

4.9 Concluding remarks

This study provides insight into the imaging GHSR in situ in DMD dilated
cardiomyopathy. With the specific probe, Cy5-ghrelin (1-19), I showed a strong positive
correlation between GHSR and inflammation markers which may suggest that GHSR could
be a possible biomarker for chronic inflammation in dilated cardiomyopathy. The negative
correlation between GHSR and LVEF proposed the GHSR as a heart function biomarker.
Despite the advancements in imaging and biomarkers research for cardiomyopathy,
distinguishing early pathogenesis and understanding disease mechanisms remain unsolved.
Innovations in early recognition of cardiomyopathy can improve the survival and quality
of life for patients and reduce the disease progression and hospital admission rate. These
advancements also can open new doors for targeted therapies. Imaging GHSR in mdx:utrn/-

mice represent a step towards the detection of early biomarkers for inflammation and

dilated cardiomyopathy.
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Appendix A. Animal research ethics approval

AUP Number: 2017-038
PI Name: Hoffman, Lisa M
AUP Title: Hoffman Breeding Protocol
Approval Date: 05/30/2017
Official Notice of Animal Use Subcommittee (AUS) Approval: Your new Animal
Use Protocol (AUP) entitled "Hoffman Breeding Protocol" has been APPROVED by the
Animal Use Subcommittee of the University Council on Animal Care. This approval,
although valid for four years, and is subject to annual Protocol Renewal.2017-038::1

1. This AUP number must be indicated when ordering animals for this project.
2. Animals for other projects may not be ordered under this AUP number.
3. Purchases of animals other than through this system must be cleared through the

ACVS office. Health certificates will be required.
The holder of this Animal Use Protocol is responsible to ensure that all associated
safety components (biosafety, radiation safety, general laboratory safety) comply
with institutional safety standards and have received all necessary approvals. Please
consult directly with your institutional safety officers.
Submitted by: Copeman, Laura
on behalf of the Animal Use Subcommittee
University Council on Animal Care
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